

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

**VOLUNTARY ANNOUNCEMENT
CHANGE IN SHAREHOLDING**

This announcement is made by Sisram Medical Ltd (the “**Company**”) on a voluntary basis.

Reference is made to the announcement of the Company on September 30, 2019 in relation to the Proposed Acquisition (the “**Previous Announcement**”). Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Previous Announcement.

As disclosed in the Previous Announcement, Ample Up, a wholly-owned subsidiary of Fosun Parma and a substantial shareholder of the Company, had entered into a sale and purchase agreement with Magnificent View, pursuant to which Ample Up agreed to acquire all of Magnificent View’s shareholding interest in the Company, which represented approximately 21.93% of the issued shares of the Company as at the date of the Previous Announcement.

On March 25, 2020, the Board was notified by Fosun Pharma that, the Proposed Acquisition has been completed in accordance with the terms of the sale and purchase agreement. Accordingly, as at the date of this announcement, Fosun Pharma, through its wholly-owned subsidiaries, holds 330,558,800 shares of the Company, which represent approximately 74.76% of the total issued shares of the Company.

On Behalf of the Board
Sisram Medical Ltd
Yi LIU
Chairman

Hong Kong, March 25, 2020

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as Executive Directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Kun DAI as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.

* *for identification purpose only*